Biotech New Lows: AVEO Pharmaceuticals (NASDAQ:AVEO), Onconova Therapeutics (NASDAQ:ONTX), BioTime (NYSEMKT:BTX), Tetralogic Pharmaceuticals (NASDAQ:TLOG)



FDA publicly (justifiably) took down AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) when patients on its drug survived less long than those in the control group. Novo Nordisk found itself years behind competitors because the FDA insists on a heart safety study of its new insulin. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) stock performance was -3.21% in last session and finished the day at $1.51. Traded volume was 730,784.00million shares in the last session and the average volume of the stock remained 626.58K shares. The beta of the stock remained 0.84. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) insider ownership is 1.50%.

One such company that looks well positioned for a solid gain, but has been overlooked by investors lately, is Onconova Therapeutics, Inc. (NASDAQ:ONTX). This biopharmaceutical stock has actually seen estimates narrowing over the past month for the current fiscal year from a loss of $2.84 a share 30 days ago. Onconova Therapeutics Inc (NASDAQ:ONTX) dropped -5.12 percent to $6.30 Friday on volume of 525,702.00million shares. The intra-day range of the stock was $6.05 to $6.70. Onconova Therapeutics Inc (NASDAQ:ONTX) has a market capitalization of $136.32million.

BioTime, Inc. (NYSEMKT:BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, PhD will present at the 2nd Annual Regen Med Investor Day to be held Wednesday, March 26, 2014 in New York City. BioTime, Inc. (NYSEMKT:BTX)’s stock on Mar 28, 2014 reported a decrease of -4.01% to the closing price of $3.11. Its fifty two weeks range is $3.01-$4.82. The total market capitalization recorded $216.45million. The overall volume in the last trading session was 373,238.00million shares. In its share capital, BTX has 56.27million outstanding shares.

“What we’re saying is in preclinical research, the majority — perhaps the vast majority — are not able to be reproduced,” said C. Glenn Begley, the chief scientific officer of biotechnology company TetraLogic Pharmaceuticals Corp (NASDAQ:TLOG) in Malvern, Penn., who formerly worked at Amgen. On Friday, shares of Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) advanced 0.33% to close the day at $6.14. Company monthly performance is recorded as -33.84%. Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) quarterly revenue growth is -25.21%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone